Skip to main content

Home/ Cancer/ Group items tagged inhibitor

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
Matti Narkia

Inhibition of suppressor T lymphocytes (Ts) by cimetidine. - J Immunol. 1987 May - 0 views

www.jimmunol.org/...2760

1987 May study research in_vivo animal_stydy contrasuppression cyclophosphamide cimetidine T-suppressor Tregs T-regs Ts inhibition inhibitors immunotherapy medline immune function immunity immunostimulants

shared by Matti Narkia on 14 Apr 09 - Cached
  • Matti Narkia on 14 Apr 09
     
    Inhibition of suppressor T lymphocytes (Ts) by cimetidine. Sahasrabudhe DM, McCune CS, O'Donnell RW, Henshaw EC. J Immunol. 1987 May 1;138(9):2760-3. PMID: 2952721 Cyclophosphamide (CY) is the most extensively studied inhibitor of suppressor T lymphocyte (Ts) function. However, repeated administration of CY can abrogate sensitization. Therefore, we were interested in identifying noncytotoxic inhibitors of Ts function as adjuncts in the immunotherapy of Ts-inducing murine tumors. The effect of cimetidine (a histamine type 2 receptor antagonist) and diphenhydramine (a histamine type 1 receptor antagonist) on the Ts mediating tolerance to 2,4-dinitrofluorobenzene was studied. We report our data regarding the specific inhibition of Ts by cimetidine.
Matti Narkia

Combination of an EGFR blocker and a COX-2 inhibitor for the treatment of advanced cuta... - 0 views

www3.interscience.wiley.com/...abstract

2008 December study case report_case_report EGFR blocker cetuximab Erbitux COX-2 inhibitor celecoxib Celebrex Celebra combination therapy treatment skin cancer skin_cancer cutaneous SCC recurrent advanced medicine

shared by Matti Narkia on 15 Mar 09 - No Cached
  • Matti Narkia on 15 Mar 09
     
    Combination of an EGFR blocker and a COX-2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma. Jalili A, Pinc A, Pieczkowski F, Karlhofer FM, Stingl G, Wagner SN. J Dtsch Dermatol Ges. 2008 Dec;6(12):1066-9. English, German. PMID: 19138272 DOI: 10.1111/j.1610-0387.2008.06861.x
Matti Narkia

Vitamin D may inhibit prostate cancer growth - mechanism reported - 0 views

www.nutraingredients.com/...ng.asp

2006 february news prostate cancer prostate_cancer PCa vitamin_D vitamin D growth-inhibitory mechanism mechanisms

shared by Matti Narkia on 24 Feb 09 - Cached
  • Matti Narkia on 24 Feb 09
     
    The in vitro study, reported in the journal Carcinogenesis (Vol. 27, pp. 32-42), showed that vitamin D, in the form of the highly active 1alpha, 25-dihydroxyvitamin D3 (1,25-VD), inhibited the function of protease enzymes that are involved in tumour invasion. "We found that 1,25-VD decreased matric metalloproteinases (MMP-9) and cathepsins (CPs), while it [also] increased the activity of their counterparts, tissue inhibitors of metalloproteinase-1 (TIMP-1) and cathepsin inhibitors," wrote lead author Bo-Ying Bao from the University of Rochester and Taipei Medical University. "Mechanistic studies showed that 1,25-VD did not suppress MMP-9 expression at the transcriptional level, but reduced its mRNA stability," said Bao.
Matti Narkia

Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumul... - 0 views

www.jhep-elsevier.com/...abstract

2009 August study research clinical_trial humans patients liver cancer liver_cancer HCC nutrition vitamin_K vitamin_K2 menatetrenone ACE-I ACE inhibitor medline recurrence risk Angiotensin-converting enzyme VEGF angiogenesis antiangiogenic

shared by Matti Narkia on 07 Dec 09 - Cached
  • Matti Narkia on 07 Dec 09
     
    Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma. Yoshiji H, Noguchi R, Toyohara M, Ikenaka Y, Kitade M, Kaji K, Yamazaki M, Yamao J, Mitoro A, Sawai M, Yoshida M, Fujimoto M, Tsujimoto T, Kawaratani H, Uemura M, Fukui H. J Hepatol. 2009 Aug;51(2):315-21. Epub 2009 May 15. PMID: 19501932 CONCLUSIONS: The combination treatment of VK and ACE-I may suppress the cumulative recurrence of HCC after the curative therapy, at least partly through suppression of the VEGF-mediated neovascularization.
Matti Narkia

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms... - 0 views

jco.ascopubs.org/...4563

2008 Ocober study research clinical_trial phase_I phase_I_trial humans men prostate cancer prostate_cancer PCa aggressive advanced castration-resistant CRPC abiraterone_acetate abiraterone CYP17 inhibitor medicine medline PSA anticacner anti-cancer

shared by Matti Narkia on 09 Apr 09 - Cached
  • Matti Narkia on 09 Apr 09
     
    Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS. J Clin Oncol. 2008 Oct 1;26(28):4563-71. Epub 2008 Jul 21. PMID: 18645193 DOI: 10.1200/JCO.2007.15.9749
Matti Narkia

Experimental Drug May Work In Many Cancers - 2 views

www.medicalnewstoday.com/...166733.php

2009 October medicalnewstoday news Experimental Drug many cancers cancer new PARP inhibitors inhibitor breast breast_cancer ovarian ovarian_cancer medicine medical

shared by Matti Narkia on 08 Oct 09 - Cached
  • Matti Narkia on 08 Oct 09
     
    "SCIENTISTS have shown that a new class of cancer drugs called PARP inhibitors, currently being tested in clinical trials to treat breast and ovarian cancer could have dramatic results when used to treat other solid tumours, according to work presented at the NCRI Cancer Conference today. "
Matti Narkia

Factors Associated With Clinical Benefit From Epidermal Growth Factor Receptor Inhibito... - 0 views

www.oncologystat.com/...noma_of_the_Head_and_Neck.html

2009 October oncologystat study review humans patients EGFR tyrosine kinase inhibitors TKI head_and_neck cancer head_and_neck_cancer hnca scchn recurrent metastatic advanced factors clinical benefits survival medline

shared by Matti Narkia on 08 Oct 09 - Cached
  • Matti Narkia on 08 Oct 09
     
    Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck. Cohen EE, Halpern AB, Kasza K, Kocherginsky M, Williams R, Vokes EE. Oral Oncol. 2009 Oct;45(10):e155-60. Epub 2009 Jul 7. PMID: 19586795
Matti Narkia

Tetrathiomolybdate: Cancer Protocol. The Treatment and Management of Cancer Today. A re... - 0 views

www.cancerprotocol.com/role_of_copper.html

Tetrathiomolybdate Cancer Protocol Treatment Management therapy anti-angiogenic anti-copper agent angiogenesis inhibition inhibitor inhibitors info information copper reduction medicine oncology imported delicious

shared by Matti Narkia on 24 Feb 09 - Cached
  • Matti Narkia on 24 Feb 09
     
    If angiogenesis controls cancer growth, what controls angiogenesis? Researchers at the University of Michigan and the University of South Florida believe that the copper status is critical to the function growth factors.
Matti Narkia

TGF-beta inhibitors: Tumors stopped from spreading to new sites - 0 views

www.eurekalert.org/...joci-tsf032907.php

TGF-beta inhibitors inhibition inhibitor cancer news control management anti-cancer agent metastases metastasis prevent prevention treatment therapy imported delicious

shared by Matti Narkia on 24 Feb 09 - Cached
  • Matti Narkia on 24 Feb 09
     
    For several types of cancer, persistently high levels of the soluble factor TGF-beta in the blood after surgery, chemotherapy, or radiation therapy correlate with increased risk of early metastasis and a poor prognosis. Using a mouse model of breast cance
Matti Narkia

Compound found in beans, nuts and cereals beats cancer (inositol pentakisphosphate) - 0 views

www.medicalnewstoday.com/...30694.php

2005 September medicalnewstoday news inositol pentakisphosphate inositol pentakisphosphate inositol_pentakisphosphate phosphoinositide_3-kinase cancer prevention beans nuts wheat_bran cereals cancer_prevention nutrition anti-cancer anticancer inhibitor

shared by Matti Narkia on 28 Mar 09 - Cached
  • Matti Narkia on 28 Mar 09
     
    A collaborative study led by UCL (University College London) shows that the compound - inositol pentakisphosphate - found in beans, nuts and cereals inhibits a key enzyme (phosphoinositide 3-kinase) involved in tumour growth. The findings, published in the latest issue of Cancer Research, suggest that a diet enriched in such foods could help prevent cancer, while the inhibitor offers a new tool for anti-cancer therapy.
Matti Narkia

Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxyg... - 0 views

clincancerres.aacrjournals.org/...5930

2004 September study research in_vitro EGFR tyrosine_kinase inhibitors inhibitor inhibition TKI TKIs Iressa gefitinib COX-2 celecoxib Celebre3x Celebra head_and_neck_cancer head_and_neck cancer SCCHN SCC HNCA synergy medicine head neck oncology

shared by Matti Narkia on 15 Mar 09 - Cached
  • Matti Narkia on 15 Mar 09
     
    Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Chen Z, Zhang X, Li M, Wang Z, Wieand HS, Grandis JR, Shin DM. Clin Cancer Res. 2004 Sep 1;10(17):5930-9. PMID: 15355926
Matti Narkia

Tetrathiomolybdate copper reduction anti-angiogenesis cancer treatment - anticopper, TM. - 0 views

www.infiltec.com/anticopper

Tetrathiomolybdate copper reduction anti-angiogenesis cancer treatment agent anti-copper angiogenesis inhibitor inhibition inhibit inhibitors guide how-to howto informative information links resources resource references info therapy medicine health impo

shared by Matti Narkia on 24 Feb 09 - Cached
  • Matti Narkia on 24 Feb 09
     
    WARNING: This page was NOT created or approved by any doctor or medical researcher. The purpose of this page is to provide hard-to-find information on copper reduction cancer treatment, a new unapproved and experimental course of cancer treatment whose ef
Matti Narkia

Tetrathiomolybdate Copper Reduction Therapy as an Antiangiogenic Treatment for Lymphoma... - 0 views

george-eby-research.com/...anti_ang.html

Tetrathiomolybdate Copper Reduction Therapy Anti-angiogenic Treatment Lymphoma cancer anti-copper agent inhibition inhibitor inhibitors guide howto how-to info information informative links resource resources reference imported delicious

shared by Matti Narkia on 24 Feb 09 - Cached
  • Matti Narkia on 24 Feb 09
     
    The article is written by lay individuals for information purposes only and is not to be used to diagnose or treat any disease. The document outlines therapeutic strategies which have not been clinically proven and may not be effective for lymphoma and ot
Matti Narkia

Copper Deficiency Induced by Tetrathiomolybdate Suppresses Tumor Growth and Angiogenesi... - 0 views

cancerres.aacrjournals.org/...4854

Copper Deficiency Tetrathiomolybdate Suppresses Tumor cancer Growth Angiogenesis anti-copper anti-angiogenesis anti-angiogenic agent inhibition inhibitor inhibitors medicine medline oncology science study research peer-reviewed treatment therapy imported

shared by Matti Narkia on 24 Feb 09 - Cached
  • Matti Narkia on 24 Feb 09
     
    Q. Pan, C. G. Kleer, K. L. van Golen, J. Irani, K. M. Bottema, C. Bias, M. De Carvalho, E. A. Mesri, D. M. Robins, R. D. Dick, G. J. Brewer, and S. D. Merajver Copper Deficiency Induced by Tetrathiomolybdate Suppresses Tumor Growth and Angiogenesis Canc
Matti Narkia

Cancer Therapy With Tetrathiomolybdate: Antiangiogenesis by Lowering Body Copper-A Revi... - 0 views

ict.sagepub.com/...327

Cancer Therapy Tetrathiomolybdate anti-angiogenesis anti-angiogenic anti-copper agent angiogenesis Copper Review reduction inhibition inhibitor inhibitors treatment science study medicine medline peer-reviewed oncology imported delicious

shared by Matti Narkia on 24 Feb 09 - Cached
  • Matti Narkia on 24 Feb 09
     
    Brewer GJ, Merajver SD. Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper--a review. Integr Cancer Ther. 2002 Dec;1(4):327-37. Review. PMID: 14664727 [PubMed - indexed for MEDLINE]
Matti Narkia

Phase II Trial of Tetrathiomolybdate in Patients with Advanced Kidney Cancer -- Redman ... - 0 views

clincancerres.aacrjournals.org/...1666

Phase-II phaseII Trial Tetrathiomolybdate Advanced Kidney Cancer renal kidneycancer clinicaltrial anti-angiogenesis anti-angiogenic anti-copper agent angiogenesis copper inhibition inhibitor inhibitors reduction medicine medline oncology science study res

shared by Matti Narkia on 24 Feb 09 - Cached
  • Matti Narkia on 24 Feb 09
     
    B. G. Redman, P. Esper, Q. Pan, R. L. Dunn, H. K. Hussain, T. Chenevert, G. J. Brewer, and S. D. Merajver Phase II Trial of Tetrathiomolybdate in Patients with Advanced Kidney Cancer Clin. Cancer Res., May 1, 2003; 9(5): 1666 - 1672.
Matti Narkia

Inhibition of the Growth of Squamous Cell Carcinoma by Tetrathiomolybdate-Induced Coppe... - 0 views

archotol.ama-assn.org/...781

Inhibition Growth Squamous Cell Carcinoma Tetrathiomolybdate Copper Suppression cancer anti-angiogenesis anti-angiogenic anti-copper agent angiogenesis inhibitor inhibitors reduction head neck scc medicine medline science study research head_and_nec SCCHN

shared by Matti Narkia on 24 Feb 09 - Cached
  • Matti Narkia on 24 Feb 09
     
    C. Cox, S. D. Merajver, S. Yoo, R. D. Dick, G. J. Brewer, J. S.-J. Lee, and T. N. Teknos Inhibition of the Growth of Squamous Cell Carcinoma by Tetrathiomolybdate-Induced Copper Suppression in a Murine Model Arch Otolaryngol Head Neck Surg, July 1, 200
Matti Narkia

Antiangiogenic Tetrathiomolybdate Enhances the Efficacy of Doxorubicin against Breast C... - 0 views

mct.aacrjournals.org/...617

anti-angiogenic anti-angiogenesis anti-copper angiogenesis Tetrathiomolybdate Doxorubicin Breast Carcinoma cancer chemotherapy agent inhibition inhibitor inhibitors copper reduction science study research medicine medline peer-reviewed impor breast_cancer

shared by Matti Narkia on 24 Feb 09 - Cached
  • Matti Narkia on 24 Feb 09
     
    Pan Q, Bao LW, Kleer CG, Brewer GJ, Merajver SD. Antiangiogenic tetrathiomolybdate enhances the efficacy of doxorubicin against breast carcinoma. Mol Cancer Ther. 2003 Jul;2(7):617-22. PMID: 12883034 [PubMed - indexed for MEDLINE]
1 - 20 of 36 Next ›
Showing 20▼ items per page